In practice, however, since β2M is expressed by all normal cells in the body, such a molecule, even if it were achievable to engineer, would likely suffer from unsurmountable target-mediated drug disposition (TMDD) and would likely be cleared before reaching the tumor site. This evidence concerns the gene B2M and neoplasm.